Natera specializes in cell-free DNA testing to elevate the science and utility of prenatal testing.
Natera specializes in cell-free DNA testing is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 15, 2022 | Post-IPO Equity | $400.05M | — | — | — | Detail |
Mar 16, 2022 | Post-IPO Equity | $5M | 2 |
![]() ![]() |
— | Detail |
Apr 13, 2020 | Post-IPO Equity | $250M | — | — | — | Detail |
Jul 10, 2015 | IPO | — | — | — | — | Detail |
Apr 6, 2015 | Series F | $55.50M | 7 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 21, 2022
![]() |
Series B | $23M | Biotechnology | — |
Jun 30, 2021
![]() |
Seed | €2.20M | Blockchain | — |
Dec 7, 2016
![]() |
Angel | €1M | Beauty | — |
Aug 2, 2015
![]() |
Seed | $189.64K | Hospitality | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Post-IPO Equity |
![]() |
Yes | Post-IPO Equity |
![]() |
Yes | Series F |
|
Yes | Series E |
![]() |
— | Series F |
![]() |
— | Series F |
![]() |
— | Series F |
![]() |
— | Series F |
![]() |
— | Series F |
![]() |
— | Series F |